GGrantIndex
← Leaderboards

Nejat K Egilmez

T And B Bioclone, Inc.

$6,728,133
Attributed
$9,473,517
Total exposure
7
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,473,517 · 7

By mechanism

R44$5,216,444 · 1
R01$2,895,362 · 1
R43$634,787 · 3
R21$452,600 · 1
T32$274,324 · 1

Top collaborators

Others in their field

Top investigators on “Cytokine

Research focus

CytokineImmuneBaseClinically RelevantDesignTumor ProgressionPharmaceutical PreparationsResponseOral AdministrationAdenomaOralNovel TherapeuticsParticulateColorectal CancerT-LymphocyteMouse ModelTumorClinical TrialsColonIntestinal PolyposisLaboratory MouseFutureProductionTumorigenesis

Grant awards (27)

IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$959,868
R44 · FY2025 · DK
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$960,296
R44 · FY2024 · DK
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$1,201,534
R44 · FY2023 · DK
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$847,546
R44 · FY2021 · DK
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$858,320
R44 · FY2020 · DK
Inflammation and Pathogenesis Training Program$134,511
T32 · FY2020 · AI · contact PI
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis$388,880
R44 · FY2019 · DK
Inflammation and Pathogenesis Training Program$139,813
T32 · FY2019 · AI · contact PI
Integrating innate and adaptive immunity in cancer therapy$301,618
R01 · FY2014 · CA · contact PI
Integrating innate and adaptive immunity in cancer therapy$281,279
R01 · FY2013 · CA · contact PI
Integrating innate and adaptive immunity in cancer therapy$299,232
R01 · FY2012 · CA · contact PI
Oral Immune Modulatory Adjuvants for Treatment of Colorectal Carcinoma$199,175
R21 · FY2012 · AI · contact PI
Integrating innate and adaptive immunity in cancer therapy$299,232
R01 · FY2011 · CA · contact PI
Oral Immune Modulatory Adjuvants for Treatment of Colorectal Carcinoma$253,425
R21 · FY2011 · AI · contact PI
Integrating innate and adaptive immunity in cancer therapy$323,112
R01 · FY2010 · CA · contact PI
Integrating Innate & Adaptive Immunity in Cancer Therapy$282,884
R01 · FY2008 · CA · contact PI
Integrating Innate & Adaptive Immunity in Cancer Therapy$286,584
R01 · FY2007 · CA · contact PI
Integrating Innate & Adaptive Immunity in Cancer Therapy$144,598
R01 · FY2006 · CA · contact PI
Integrating Innate & Adaptive Immunity in Cancer Therapy$121,087
R01 · FY2006 · CA · contact PI
Integrating Innate &Adaptive Immunity in Cancer Therapy$272,844
R01 · FY2005 · CA
Integrating Innate &Adaptive Immunity in Cancer Therapy$282,892
R01 · FY2004 · CA
Interleukin10 Microsphere in Inflammatory Bowel Disease$16,152
R43 · FY2002 · DK
BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY$15,600
R43 · FY2002 · CA
BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY$209,629
R43 · FY2001 · CA
BIODEGRADABLE MICROSPHERES FOR CANCER IMMUNOTHERAPY$99,906
R43 · FY2001 · CA
Interleukin10 Microsphere in Inflammatory Bowel Disease$99,500
R43 · FY2001 · DK
BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY$194,000
R43 · FY2000 · CA